Marina's nucleic acid delivery hits the ground running in its first human Phase I trial

October 05, 2010 | Analyst Insight

Marina Biotech recently announced the first human use of its Smarticles nucleic acid delivery targeting cancer treatment. In this Phase I study, its partner ProNAi Therapeutics utilizes the liposome-based Smarticles...